CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.660 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Apple, Amazon, HP And Other Big Losers From Friday ↗

August 29, 2022

U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday ↗

August 29, 2022

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.

Via Benzinga

Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗

August 26, 2022

Moderna Inc (NASDAQ: MRNA) has

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

August 25, 2022

On Thursday, 63 companies set new 52-week lows.

Via Benzinga

Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation ↗

August 18, 2022

Via Benzinga

Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029 ↗

April 11, 2022

Via Benzinga

CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial ↗

March 30, 2022

Via Benzinga

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

August 18, 2022

Via ACCESSWIRE

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

August 18, 2022

Via ACCESSWIRE

BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac ↗

July 26, 2022

Via Benzinga

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 06, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗

July 05, 2022

The company isn't seeking an injunction, but wants "fair compensation."

Via Investor's Business Daily

CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech ↗

July 05, 2022

Via Benzinga

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

July 05, 2022

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

Topics Intellectual Property Lawsuit

CureVac Announces Voting Results of General Meeting

June 22, 2022

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...

From CureVac

Via AccessWire

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

June 08, 2022

TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on...

From CureVac

Via AccessWire

CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen

June 08, 2022

TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

Billionaire Bill Gates Is Betting Against TSLA Stock. Here’s Where He’s Putting His Money Instead. ↗

May 25, 2022

Earlier this year, it was revealed that Bill Gates had a half a billion dollar short position against TSLA stock. So, what is he bullish on?

Via InvestorPlace

The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine ↗

May 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

May 25, 2022

TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update

May 25, 2022

TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗

April 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

April 28, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From CureVac

Via AccessWire

How To Attend CureVac Q4 2021 Earnings Conference Call ↗

April 25, 2022

CureVac (NASDAQ:CVAC) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q4 2021 earnings results. How to Attend CureVac (CVAC) Conference Call Follow this link to access the live...

Via Benzinga

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

April 22, 2022

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗

April 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

April 21, 2022

- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron...

From CureVac

Via AccessWire

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

April 11, 2022

- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million...

From CureVac

Via AccessWire

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

March 30, 2022

- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine...

From CureVac

Via AccessWire

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)

March 01, 2022

- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics - CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate...

From CureVac

Via AccessWire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.